Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on biomarkers and frailty
Arden, Nigel, Richette, Pascal, Cooper, Cyrus, Bruyère, Olivier, Abadie, Eric, Branco, Jaime, Brandi, Maria Luisa, Berenbaum, Francis, Clerc, Cécile, Dennison, Elaine M., Devogelaer, Jean-Pierre, Hochberg, Marc, D'Hooghe, Pieter, Herrero-Beaumont, Gabriel, Kanis, John A., Laslop, Andrea, Leblanc, Véronique, Maggi, Stefania, Mautone, Giuseppe, ... Reginster, Jean-Yves. (2015). Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on biomarkers and frailty. Drugs and Aging. 32(7), pp. 525 - 535. https://doi.org/10.1007/s40266-015-0276-7
|Authors||Arden, Nigel, Richette, Pascal, Cooper, Cyrus, Bruyère, Olivier, Abadie, Eric, Branco, Jaime, Brandi, Maria Luisa, Berenbaum, Francis, Clerc, Cécile, Dennison, Elaine M., Devogelaer, Jean-Pierre, Hochberg, Marc, D'Hooghe, Pieter, Herrero-Beaumont, Gabriel, Kanis, John A., Laslop, Andrea, Leblanc, Véronique, Maggi, Stefania, Mautone, Giuseppe, Pelletier, Jean-Pierre, Petit-Dop, Florence, Reiter-Niesert, Susanne, Rizzoli, Rene, Rovati, Lucio C., Messi, Eleonora Tajana, Tsouderos, Yannis, Martel-Pelletier, Johanne and Reginster, Jean-Yves|
Osteoarthritis (OA), a disease affecting different patient phenotypes, appears as an optimal candidate for personalized healthcare. The aim of the discussions of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group was to explore the value of markers of different sources in defining different phenotypes of patients with OA. The ESCEO organized a series of meetings to explore the possibility of identifying patients who would most benefit from treatment for OA, on the basis of recent data and expert opinion. In the first meeting, patient phenotypes were identified according to the number of affected joints, biomechanical factors, and the presence of lesions in the subchondral bone. In the second meeting, summarized in the present article, the working group explored other markers involved in OA. Profiles of patients may be defined according to their level of pain, functional limitation, and presence of coexistent chronic conditions including frailty status. A considerable amount of data suggests that magnetic resonance imaging may also assist in delineating different phenotypes of patients with OA. Among multiple biochemical biomarkers identified, none is sufficiently validated and recognized to identify patients who should be treated. Considerable efforts are also being made to identify genetic and epigenetic factors involved in OA, but results are still limited. The many potential biomarkers that could be used as potential stratifiers are promising, but more research is needed to characterize and qualify the existing biomarkers and to identify new candidates.
|Journal||Drugs and Aging|
|Journal citation||32 (7), pp. 525 - 535|
|Publisher||Springer International Publishing|
|Digital Object Identifier (DOI)||https://doi.org/10.1007/s40266-015-0276-7|
|Open access||Open access|
|Page range||525 - 535|
|Research Group||Institute for Health and Ageing|
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
|Place of publication||Switzerland|
0views this month
0downloads this month